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Abstract
In the canonical model of smooth muscle (SM) contraction, the contractile force is generated by phosphorylation of the
myosin regulatory light chain (RLC20) by the myosin light chain kinase (MLCK). Moreover, phosphorylation of the myosin
targeting subunit (MYPT1) of the RLC20 phosphatase (MLCP) by the RhoA-dependent ROCK kinase, inhibits the phosphatase
activity and consequently inhibits dephosphorylation of RLC20 with concomitant increase in contractile force, at constant
intracellular [Ca2+]. This pathway is referred to as Ca2+-sensitization. There is, however, emerging evidence suggesting that
additional Ser/Thr kinases may contribute to the regulatory pathways in SM. Here, we report data implicating the p90
ribosomal S6 kinase (RSK) in SM contractility. During both Ca2+- and agonist (U46619) induced SM contraction, RSK
inhibition by the highly selective compound BI-D1870 (which has no effect on MLCK or ROCK) resulted in significant
suppression of contractile force. Furthermore, phosphorylation levels of RLC20 and MYPT1 were both significantly
decreased. Experiments involving the irreversible MLCP inhibitor microcystin-LR, in the absence of Ca2+, revealed that the
decrease in phosphorylation levels of RLC20 upon RSK inhibition are not due solely to the increase in the phosphatase
activity, but reflect direct or indirect phosphorylation of RLC20 by RSK. Finally, we show that agonist (U46619) stimulation of
SM leads to activation of extracellular signal-regulated kinases ERK1/2 and PDK1, consistent with a canonical activation
cascade for RSK. Thus, we demonstrate a novel and important physiological function of the p90 ribosomal S6 kinase, which
to date has been typically associated with the regulation of gene expression.
Citation: Artamonov M, Momotani K, Utepbergenov D, Franke A, Khromov A et al. (2013) The p90 Ribosomal S6 Kinase (RSK) Is a Mediator of Smooth Muscle
Contractility. PLoS ONE 8(3): e58703. doi:10.1371/journal.pone.0058703
Editor: Agustin Guerrero-Hernandez, Cinvestav-IPN, Mexico
Received October 4, 2012; Accepted February 5, 2013; Published March 13, 2013
Copyright:  2013 Artamonov et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported in part by the University of Virginia Cancer Center through the NCI Cancer Center Support Grant (P30CA44579) and in part
by the National Institutes of Health (R01GM86457 to ZSD and AVS, and R01DK088905 to AVS). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: avs5u@virginia.edu
. These authors contributed equally to this work.
Introduction
Contraction and relaxation of smooth muscle (SM), which is
found in the walls of blood vessels, lymphatic vessels, bladder,
uterus, the gastrointestinal, respiratory and reproductive tracts, as
well as other hollow organs, play a critical role in the regulation of
blood pressure, pulmonary resistance, gastrointestinal motility,
urogenital and erectile function [1]. Like all muscle types, SM cells
contract in response to Ca2+ influx through membrane channels
and Ca2+ release from the sarcoplasmic reticulum, which drive the
highly conserved cross-bridge cycle [2]. In SM, contraction is
induced when Ca2+-bound calmodulin binds to and activates the
myosin light chain kinase (MLCK), which phosphorylates the
regulatory myosin light chain (RLC20) on Ser19, with concomitant
activation of the ATPase activity of myosin [1]. Conversely,
dephosphorylation of RLC20 by the RLC20-phosphatase (MLCP)
inhibits contraction and induces relaxation [3,4].
Over the past two decades, it has been shown that this relatively
simple Ca2+/calmodulin-dependent paradigm is additionally
modulated in a complex and often tissue-specific way by
phenomena which are Ca2+-independent and which amplify the
contractile response to Ca2+, leading to ‘Ca2+ sensitization’ [5,6].
Two distinct molecular mechanisms have been reported for this
pathway. The first of these invokes Ca2+-independent activation of
kinases other than MLCK, capable of direct phosphorylation of
RLC20. The second mechanism involves agonist-dependent down-
regulation of MLCP, leading to increased contractility at constant
intracellular Ca2+ concentration ([Ca2+]i). The release of select
agonists (e.g. thromboxane A2), which act on G-protein coupled
receptors (GPCRs), up-regulates the cytosolic GTPase RhoA,
which in turn activates the Rho-associated protein kinase-ROCK.
The latter phosphorylates the myosin targeting subunit (MYPT1)
of the heterotrimeric MLCP, made up also of the catalytic subunit
(PP1C) and a 21 kDa subunit [7,8]. Phosphorylation of MYPT1
leads to inhibition of the phosphatase activity of PP1C,
consequently sustaining RLC20 phosphorylation and thus enhanc-
ing the SM contractile force. Interestingly, both Ca2+ independent
ZIPK and ILK also phosphorylate MYPT1 and suppress PP1C
activity [9,10].
Although Ca2+-sensitization is now recognized as a major
regulatory mechanism in SM, and is targeted for such conditions
as hypertension, it is also increasingly clear that additional
regulatory mechanisms, both Ca2+-dependent and independent,
must be in place in diverse SM tissues. Evidence for Ca2+-
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independent activity is seen when microcystin-LR, a phosphatase
inhibitor, is added to permeabilized SM in the absence of [Ca2+]i
[11]; under these conditions the level of phosphorylation of RLC20
increases, resulting in contraction. It has also been shown that the
blood vessels isolated from MLCK-null mice embryos at E14.5 to
term and permeabilized with a-toxin, develop force in response to
increase in [Ca2+]i, [12]. Moreover, Ca
2+-sensitization can be
induced in MLCK-null vessels by addition of GTPcS and this
contraction can be relaxed by the Rho-kinase inhibitor, Y-27632
[12]. Thus, the MLCK (-/-) SM seems to utilize Ca2+ dependent
kinase(s) other than MLCK, or/and Ca2+-independent kinase(s)
which are activated by Ca2+-dependent upstream signaling.
Interestingly, it has been reported some time ago that the p90
ribosomal S6 kinase (RSK2), which is typically associated with
regulation of gene expression, can phosphorylate RLC20 in vitro,
although the physiological consequences have never been explored
[13]. The four known RSK isoforms (RSK1-4), as well as the
related mitogen- and stress-activated kinases MSK1 and MSK2,
display unique molecular architecture, with two distinct protein
Ser/Thr kinase domains in tandem, i.e. the regulatory C-terminal
kinase domain (CTKD), and the physiologically active N-terminal
kinase domain (NTKD) [14,15,16]. The activation of RSK kinases
involves several sequential phosphorylation steps, initiated by the
docking of extracellular signal-regulated kinases (ERK1/2) at the
C-terminus and subsequent phosphorylation and activation of
CTKD, intramolecular phosphorylation of the interdomain linker
at Ser380, the recruitment of active phosphoinositide-dependent
kinase 1 (PDK1) to this newly phosphorylated site, and finally
PDK1-dependent phosphorylation of Ser227 (RSK2 numbering)
within the T-loop, with concomitant activation of the NTKD [15].
Both ERK1/2 and PDK1 kinases are known to function in SM,
and have been implicated in some tissues in regulation of SM
proliferation and contractility [17,18,19].
Since the original observation of RLC20 phosphorylation by
RSK2 was reported, two selective inhibitors for the RSK family of
kinases were discovered: the flavonoid glycoside SL0101 [20] and
the synthetic compound BI-D1870 [21]. In the present study we
took advantage of these reagents to investigate if RSK plays a role
in SM contractility using ex vivo assays. We show that inhibition of
RSK significantly reduces contractile response in intact SM
stimulated by either high [K+] or the thromboxane A2 (TXA2)
analogue U46619, which typically induces Ca2+-sensitization
cascade through the activation of the TXA2 receptors and the
RhoA/ROCK signaling cascade. Furthermore, RSK inhibition by
BI-D1870 significantly reduces phosphorylation levels of both
RLC20 and MYPT1, and suppresses agonist induced Ca
2+-
sensitized force, indicating that RSK functions in SM not only
through phosphorylation of RLC20 but also through inhibitory
phosphorylation of MYPT1. Further evidence for agonist-induced
activation of RSK in SM is our finding that the TXA2 receptor
synthetic agonist U46619 increases ERK1/2 and RSK2 Ser227
phosphorylation. Interestingly, our data also suggest that RSK up-
regulation leads to the phosphorylation of the MYPT1 subunit not
only at the canonical sites of Thr853 and Thr696, but also on
Ser668.
Materials and Methods
Tissue preparation and force measurements
All procedures and protocols were approved by the Animal
Care and Use Committee at the University of Virginia (Protocol
#1834 for rabbit and rat, and Protocol #2796 for mice). The
primary branches of the rabbit pulmonary artery were dissected,
freed from connective tissue, cut into small strips (150–250 mm
wide, 2–3 mm long) and mounted between two tungsten hooks on
a bubble plate for force measurements [22,23]. Following
equilibration, intact strips were stimulated with high [K+]
(179 mM) Hepes buffered solution or 300 nM U46619 in the
presence of 25 nM, 100 nM or 1 mM BI-D1870 or matching
diluent concentration, (DMSO) and the magnitude of contraction
measured.. Strips were also permeabilized with 500 U/ml
Staphylococcus aureus a-toxin [23] or 75 mM b-escin [24] in relaxing
solution (G1) containing 4.5 mM MgATP and 1 mM EGTA. To
deplete Ca2+ stores, strips were treated with 10 mM Ca ionophore
A23187 (Calbiochem) for 10–15 min in G1. For Ca2+-activating
solutions, 10 mM EGTA was used and a calculated amount of
Ca2+-methanesulfonate was added to give the desired [Ca2+].
Measurements of IC50 for RSK and PDK inhibitors were carried
out in muscle strips stimulated with pCa 6.7. Once the force
reached a plateau, increasing concentrations of inhibitors or of the
diluent (DMSO) were added, and the magnitude of force
relaxation was recorded. The magnitude of relaxation was
normalized to that of the pCa 6.7-induced force, taken as 100%.
The dependence of force developed in response to varying
[Ca2+] was determined by activating the strips by increasing
[Ca2+] from pCa.8. Muscle strips were preincubated with
100 nM of BI-D1870 or 30 mM GSK2334470 or the correspond-
ing concentrations of DMSO as control, for 15 min in relaxing
(G1) solution and then stimulated with Ca2+-activating solutions to
allow for the magnitude of the force response to be measured.
Force was normalized to maximal Ca2+-induced force (pCa 4.5)
taken as 100%, or expressed as the absolute value in milli-Newtons
(mN).
For Ca2+-sensitization experiments, the muscle strips were
preincubated with the RSK inhibitor BI-D1870 (1 mM) or the
PDK1 inhibitor GSK2334470 (30 mM), or corresponding con-
centrations of DMSO for 15 min in relaxing (G1) solution at low
pCa 7.0 (agonist-sensitized force) and once the force reached a
plateau, strips were Ca2+-sensitized by the addition of the TXA2
receptor agonist (U46619, 300 nM). Up to 1–2 mM of GTP was
added together with the sensitizing agonist U46619 to compensate
for possible loss of GTP during permeabilization. In the presence
of inhibitor, the force was normalized to the magnitude of agonist-
induced Ca2+ sensitized force on the same strip, recorded in the
absence of inhibitor and taken as 100%. Tissue samples were
frozen in relaxing solution, at the peak of agonist activation or
maximal Ca2+ stimulation, in the presence and absence of
inhibitors for biochemical assays for RLC20 phosphorylation on
Ser19 and MYPT1 on Thr853, as well as RSK2 phosphorylation
on Ser227, MYPT1 on Ser668, ERK1/2 on Ser217/221, and
PDK on Ser241. In some experiments, unphosphorylated, mono-
and di-phosphorylated RLC20 were separated on urea gels.
For experiments designed to evaluate the contribution of Ca2+-
independent kinases to contraction of SM in the absence of MLCP
activity, the following protocol was used: following permeabiliza-
tion with b-escin (75 mM) to allow for the penetration of the
microcystin-LR, the strips were preincubated with of BI-D1870
(1 mM), or the corresponding concentration of DMSO for 5 min
in relaxing (G1) solution, plus 1 mM calmodulin for 15 min
followed by addition of microcystin-LR (10 mM). Temperature
was 22–24uC. After the force reached the plateau, the strips were
snap-frozen in 10% TCA in acetone at 280uC for further
biochemical studies. The force was normalized to agonist-induced
Ca2+ sensitized force, taken as 100%.
For evaluation of the effect of BI-D1870 and GSK2334470 on
crossbridge cycling, 0.2 mm diameter strips of mouse ileum were
permeabilized with 0.5% Triton X-100 in G1 solution in the
presence of myokinase inhibitor Ap5A, which inhibits ATP
RSK Kinase in Smooth Muscle Contractility
PLOS ONE | www.plosone.org 2 March 2013 | Volume 8 | Issue 3 | e58703
synthesis, (50 mM) for 20 mins. Following washing off Triton and
treatment with A23187, an ionophore that depletes Ca2+-stores
(10 mM) for 15 mins, the muscles were washed with ATP-free
‘‘rigor’’ solution with Ca2+ and irreversibly phosphorylated by
endogenous MLCK with 1 mM ATPcS as published previously
[25]. Upon extensive washing in Ca2+- and ATP-free solution, the
muscle strips were activated with 4.5 mM of MgATP in the
absence of Ca (G10) with our without BI-D1870 or GSK2334470.
The half-time of the rate of force development was used as an
index of the actomyosin ATPase rate.
Tissue screen and western blots
SM tissues and brain were harvested from rabbits and mice, and
screened for expression of RSK1, RSK2 and RSK3. Tissues and
cultured cells were lysed in lysis buffer (1% Triton X-100, 150 mM
NaCl, 1 mM EDTA, 50 mM Tris-HCl pH 7.5, 1 mM dithio-
threitol, 1% protease inhibitor cocktail (SIGMA) for mouse tissues
and 1% SDS, 300 mM NaCl, 50 mM Tris-HCl pH 7.5 for all
other samples), subjected to SDS-PAGE, transferred to poly-
vinylidene difluoride membrane (Millipore) and visualized using
the Odyssey System (Li-Cor, Lincoln, NE). To examine the
phosphorylation of MYPT1 and RLC20, rabbit pulmonary artery
SM strips were treated as described above. Following the
stimulation protocols, muscle strips were immediately frozen by
immersion in 280uC 10% (wt/vol) trichloroacetic acid in acetone
and stored at 280uC. Frozen strips were then washed in acetone
and dried, homogenized in sample buffer in a glass-glass, hand-
operated homogenizer and phosphorylation was estimated by
SDS-PAGE and Western blotting. For imaging, the membranes
were blocked with the Odyssey blocking buffer. The membranes
were subjected to anti- RSK1 (1:500), RSK2 (1:500), total MYPT1
(1:2,000), phospho-MYPT1 (Thr668) (1:1,000), phospho-MYPT1
(Thr853) (1:1,000), phospho-MYPT1 (Thr696) (1:1,000) and
phospho-RLC20 (1:500), phospho-RSK2 (Ser227) (1:500), RSK3
(1:500), total RLC20 (1:5000) antibodies also: ERK1/2, phospho-
PDK1 (Ser241) (1:500). Antibodies were diluted in Odyssey
blocking buffer. The membranes were washed in TBS with 0.05%
Tween 20. Primary antibodies were visualized using secondary
antibodies conjugated to either Alexa 680 or IRDye800 for
Odyssey imaging.
Preparation of GFP-ZIP kinase c phosphate-linked
sepharose
Gamma phosphate linked ATP sepharose resin was prepared as
previously published [26]. The resin was mixed with HEK293 cell
extract expressing full length ZIPK fused to GFP. After washing,
the resin was divided and eluted with the BI-D1870 (50 mM) or
100 mM ATP. The 100 mM ATP represents a maximal signal
while the minimal signal is the blank buffer with the BI-D1870
diluent DMSO.
Preparation of recombinant RSK2
DNA fragment encoding amino acids 44–728 of murine RSK2
was amplified by Phusion polymerase and cloned into pFast-
BacHTb vector using BamHI and SalI sites. Recombinant virus
was generated with Bac-to-Bac system and amplified in Sf-9 cells.
For RSK2 overexpression, two 500 ml cultures of Sf-9 cells were
infected with 5 ml of viral stock. Cells were harvested after 60 hrs
and frozen at 280uC. Cell pellets were thawed in 100 ml of lysis
buffer (50 mM Tris pH 8.0, 500 mM NaCl, 5 mM 2-mercapto-
ethanol and 1% Igepal CA-630) and homogenized in Dounce
homogenizer. Cell lysate was clarified by centrifugation for 35 min
at 100,000 g and subsequently incubated for 1 hr with 2 ml His-
Select resin. After extensive washes the protein was eluted and
further purified with size-exclusion chromatography over Sepha-
dex 200 column. His-tag was not removed.
Reagents
GSK 2334470 and SL0101 were purchased from Tocris
Bioscience (Bristol, UK); BI-D1870 from Enzo Life Sciences
(USA); Microcystin-LR and U46619 from Calbiochem (La Jolla,
CA, USA); b-escin from Sigma (USA). The RSK1, RSK2,
MYPT1, phospho-MYPT1 (Thr668), phospho-MYPT1 (Thr853
and Thr696), and phospho-RLC20 antibodies were purchased
from Cell Signaling Technology, MA, USA; phospho-
RSK2(Ser227) and RSK3 from Santa Cruz Biotechnology;
RLC20 from Sigma; ERK1/2 and phospho-PDK1(Ser241)
antibodies from Thermo Scientific, Il, USA, secondary antibodies
from Invitrogen or Li-Cor, Lincoln, NE, for Odyssey imaging.
Data analysis
Force responses to treatments were fit using GraphPad Prizm
5.0 software (GraphPad Software, Inc., CA). The significance of
the difference between curves was determined using two-way
analysis of variance. The P values for differences between curves
are presented on each graph. Mean values and standard error of
the mean (S.E.M.) were obtained from 3–8 independent exper-
iments for each condition. Statistical significance of group
differences was assessed using Student’s t-test. The level of
significance was set at p,0.05.
Results
Identification of RSK isoforms in rabbit and mouse
smooth muscle tissues
Given the reported observation that the RSK2 isoform can
phosphorylate RLC20 in vitro [13], we wondered if RSK kinases
play a physiological role is SM contractility. We began by
determining which of the four RSK isoforms might be functional
in SM. Of the four known isoforms, RSK4 is the least abundant,
and in the few tissues where it is present, it is constitutively active
[27]. Therefore, we ruled out this isoform. To search for the
remaining proteins we used three specific commercial antibodies
for RSK1, RSK2 and RSK3. As a control we used recombinant
RSK2 protein, and as expected only the anti-RSK2 antibody
reacted with this sample (Figure S1A). Tissue screens for the three
RSK isoforms were carried out in rabbit and mouse vascular beds
and the gastrointestinal tract. The RSK3 isoform was not detected
in any rabbit tissues (data not shown), which may reflect poor
reactivity of the RSK3 antibody. Only very weak signals for RSK3
were detected in mouse bladder, portal vein and thoracic aorta
(data not shown). In contrast, RSK2 was detected in all SM tissues
tested while RSK1 was detected in rabbit but not mouse SM,
except for mouse brain (mouse data not shown). The antigenic
amino acid sequence of RSK1 is identical for rabbit, mouse and
human (Figure S1C), and therefore the lack of a positive result in
mouse is not due to differences in the antigenic sites for the two
species. Although our data strongly suggest that the isoform active
in SM is RSK2, the definitive clarification of which RSK
isoform(s) play a role in SM contractility remains to be
determined. Therefore, throughout the paper we use the generic
term RSK when referring to the target kinase.
RSK Kinase in Smooth Muscle Contractility
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Inhibition of RSK suppresses high [K+]- and U46619-
induced force in intact SM
We first examined whether the BI-D1870 compound, which is a
selective inhibitor for the RSK family of Ser/Thr kinases [28,29]
has an effect on SM contractility. Intact strips of rabbit pulmonary
artery were stimulated with high [K+] in the presence of 25 nM,
100 nM and 1 mM BI-D1870, or the DMSO diluent. The initial
large phasic component of force was significantly suppressed at the
1 mM BI-D1870 concentration (Figure 1). We then analyzed
changes in U46619-induced contraction in the presence of the
Rho kinase inhibitor Y-27632 and/or BI-D1870 in intact SM.
High [K+]-induced contraction was used as a reference (i.e. 100%)
to assure that the magnitude of U46619-induced contraction was
significant and to compare magnitudes of contraction among
different treatments. As a result, addition of Y-27632 together with
BI-D1870 prior to activation with U46619 (300 nM) inhibited the
contraction to a greater extent that Y-27632 alone (Figure 2A),
suggesting that the inhibitory effects of the BI-D1870 are not due
to the inhibition of ROCK. Contraction in response to stimulation
of intact muscle with 300 nM of U46619 was suppressed by
100 nM BI-D1870, (Figure 2B). These findings strongly suggest a
physiological role for RSK kinases in SM contractility, but because
of the complexity of the signaling in intact SM involving ion
channels, second messengers and Ca2+, we focused specifically on
Ca2+-dependent and independent mechanisms, as well as RhoA-
mediated Ca2+ sensitized force, using permeabilized SMs.
RSK mediates Ca2+-induced SM contractile force by
increasing phosphorylation of both RLC20 and MYPT1
Using strips dissected from rabbit pulmonary arteries and
permeabilized with a-toxin (see Materials and Methods), we
directly measured the contractile force generated by an increase in
[Ca2+] in the absence of inhibitors and then in the presence BI-
D1870 (100 nM). In the presence of the inhibitor, we observed
two distinct effects: the onset of contraction was shifted to higher
[Ca2+] and the maximum force was significantly reduced (,65%)
as compared for the control samples treated only with the diluent
DMSO (Figure 3A). We also determined the IC50 value for BI-
D1870, which was ,17 nM (Figure S2). The RSK inhibitor
SL0101 [20] (30 mM) also reduced Ca2+-induced force, but due to
its poor solubility, it has not been possible to credibly quantify the
data (Figure 2).
Although we expected that the observed effects of BI-D1870
may be due to suppression of direct phosphorylation of the RLC20,
the contractile force can be also affected negatively by up-
regulation of the MLCP activity. Therefore, we checked if the
effect of the RSK inhibitor is correlated with a decrease in
phosphorylation of RLC20 or/and MYPT1. Using phospho-
specific antibodies, we determined that in permeabilized rabbit
arteries preincubated for 15 min at pCa 4.5 in the presence of
100 nM BI-D1870, phosphorylation levels of RLC20 on Ser19 and
of MYPT1 on Thr853 (the main ROCK inhibitory site) were both
significantly decreased (Figure 3B). The BI-D1870-induced
decrease in Ca2+-mediated RLC20 phosphorylation may reflect
its direct or indirect phosphorylation by RSK or is secondary to
the decrease in MYPT1 Thr853 phosphorylation and increased
phosphatase activity.
To rule out the possibility that the inhibitory effects of BI-
D1870 or GSK2334470 on contraction are due to inhibition of
actomyosin ATPase activity, we measured the rate of ATP-
induced force in Triton permeabilized SM with thiophosphory-
lated RLC20 in Ca
2+ free rigor solution (ATP free) The presence of
BI-D1870 (100 nM) (Figure 3C) or GSK2334470 (30 mM) (data
not shown) had no significant effect on the cycling of phosphor-
ylated crossbridges (t1/2= 4.861.2 sec Control (DMSO) vs
5.061.3 sec BI-D1870, p = ns, n= 3 and t1/2= 5.160.8 Control
(DMSO) vs 5.460.2 GSK2334470, p= ns, n = 3).
The constitutively active PDK1 kinase is required for upstream
activation of RSK [15,30]. To clarify if PDK1 is also involved in
the RSK-mediated SM contractility, we treated the a-toxin
permeabilized pulmonary artery SM with the selective PDK1
inhibitor, GSK2334470 (30 mM). The treatment resulted in a
significant decrease in the contractile force in response to [Ca2+]
(Figure 3D) along with reduction in phosphorylation of MYPT1
on Thr696 to ,50%, on Thr853 to ,75%, and concomitant
reduction in phosphorylation of RLC20 at Ser19 to ,60% as
compared to control experiments (data not shown). These results
conclusively implicate the involvement of canonical regulatory
mechanisms for RSK in SM contractile regulation.
The MLCP-independent activity of RSK in smooth muscle
The potent, irreversible inhibitor of MLCP, microcystin-LR
(microcystin), is routinely used as a reagent that allows the study of
signaling phenomena independent of MLCP. In a control
experiment using a rabbit pulmonary artery permeabilized with
b-escin, microcystin induces a slow contraction at pCa 9.0 (1 nM
Ca2+), i.e. with [Ca2+] well below normal contraction threshold
(pCa 7.0), which attests to the phosphorylation of RLC20 catalyzed
by Ca2+-independent kinases. We asked what effect BI-D1870 had
under the conditions of this experiment. The addition of the
inhibitor significantly increased the lag time to the onset of force
measured at the intercept of the baseline with a straight line fitted
to the rising phase (2.7 min60.4 vs 4.7 min60.7, p,0.01 n= 11);
and the rate of force development (t K=11 vs 17 min, p,0.02)
(Figure 4). BI-D1870 treatment also decreased microcystin-
induced RLC20 phosphorylation (Figure 4), measured at 25 min
following addition of microcystin and normalized to the value in
the diluent (1.060.24 vs 0.760.06, p,0.03, n= 5). This may be
an underestimate of Ser19 phosphorylation as microcystin
Figure 1. The RSK inhibitor BI-D1870 inhibits the contractile
response to high [K+] stimulation of intact rabbit pulmonary
artery. High [K+] (179 mM) stimulation was carried out in the presence
of 25 nM, 100 nM and 1 mM BI-D1870 and on paired muscle strips the
corresponding concentrations of the diluent DMSO were used as
indicted. 1 mM BI-D1870 significantly inhibited both the phasic and
tonic component of contraction.
doi:10.1371/journal.pone.0058703.g001
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treatment leads to phosphorylation of Ser19 and Thr18 and the
phospho-Ser19 specific antibody may not recognize the RLC20
phosphorylated at both Ser19 and Thr18 [31]. Subsequent
addition of Ca2+ to the sample containing both microcystin and
BI-D1870 resulted in a further increase of force to 7765.5% vs
7964.3% for the diluent expressed as% maximal contraction with
pCa 4.5 measured prior to treatment with microcystin providing
additional evidence that BI-D1870 did not inhibit MLCK.
To address the possibility that the inhibition of the microcystin-
induced contraction by BI-D1870 was due to the inhibition of the
Ca2+ independent ZIP kinase [32], we tested the ability of BI-
D1870 (50 mM) to elute full length GFP-ZIPK bound through its
nucleotide binding site to a c-phosphate linked ATP-sepharose
column [26]. While 100 mM ATP (used for the maximal signal)
readily eluted GFP-ZIPK from the column, BI-D1870, a known
potent ATP-competitive inhibitor of RSK isoforms [28] was
without effect (Figure 5). Thus it is highly unlikely that the BI-
D1870 inhibition of the Ca2+ independent microcystin-induced
contraction is through inhibition of ZIP Kinase.
RSK mediates agonist-induced, Ca2+-sensitized force
We next asked if agonist stimulation might also up-regulate
RSK and mediate SM contractility in a Ca2+-independent
manner, targeting MYPT1 and consequently MLCP. We used
an assay involving the synthetic agonist U46619 for the
thromboxane A2 (TXA2) receptor.
The U46619-induced force in the permeabilized rabbit
pulmonary artery SM at constant [Ca2+] (pCa 7.0) was suppressed
in the presence of 100 nM BI-D1870 by more than ,50%
compared with untreated control (Figure 6A and B). When
GTPcS was added to the control sample and the sample with BI-
D1870, the same level of contractile force was recorded, attesting
to the fact that maximal activation of RhoA by GTPcS
compensated for the BI-D1870 mediated inhibition of Ca2+-
sensitized force (Figure 6A). Phosphorylation of RLC20 at Ser19 as
well as MYPT1 at both the Thr853 and Thr696 inhibitory sites,
associated with U46619 induced force, was significantly decreased
in the presence of BI-D1870 (Figure 6C). Because the phospho-
specific RLC20 antibody is less sensitive when both the Ser19 and
Thr18 sites are phosphorylated [31], urea gels were used to
separate singly and doubly phosphorylated light chains (Figure 6D).
U46619-induced Ca2+ sensitized force resulted in only singly
phosphorylated RLC20 and this decreased with BI-D1870
treatment confirming that RSK activation results in phosphory-
lation at the Ser19 site (Figure 6C). Stimulation of the
permeabilized rabbit pulmonary artery SM with U46619 at
constant [Ca2+] (pCa 7.0) also induced an increase in phosphor-
ylation of RSK2 at Ser227 and its upstream regulator ERK1/2
(Figure 6E) indicating activation of RSK occurring through the
canonical MEK/ERK pathway.
Given that the MEK/ERK pathway also depends on the
constitutive activity of the PDK1 kinase, we asked if inhibition of
PDK1 might alter contraction of SM. An increase in phosphor-
ylation of PDK1 was also detected after stimulation with U46619
(Figure 6E). When PDK1 was inhibited by its selective inhibitor
GSK2334470 (30mM), U46619 induced Ca2+-sensitized force was
suppressed by ,40% compared with untreated rabbit pulmonary
artery SM (Figure 6B) along with concomitant decrease in
MYPT1 phosphorylation at both Thr853 to (4063% as compared
to control, n = 3, p,0.01) and at Thr696 to (55625% as
compared to control, n = 3, p,0.01) (data not shown). Taken
together, these series of results suggest involvement of RSK under
the MEK/ERK pathway in the Ca2+-sensitization pathway of SM
regulation.
Potential phosphorylation of MYPT1 on ser668 by RSK
An analysis of the amino acid sequence of MYPT1 revealed a
third potential RSK phosphorylation motif (RRXS/T) which
includes Ser668. We found that in intact pulmonary arteries, the
phosphorylation level of MYPT1 at Ser668 increased by
Figure 2. Inhibition of ROCK does not inhibit the ability of the RSK inhibitor BI-D1870 to suppress the high [K+] contraction and BI-
D1870 significantly suppresses U46619-induced force in intact pulmonary artery. (A) Pretreatment of intact SM with the ROCK inhibitor,
Y-27632 or Y-27632 plus BI-D1870 prior to stimulation with U46619. Force responses were normalized to the KCL-induced contraction taken as 100%.
(B) Pretreatment of intact SM with 25 nM, 100 nM and 1 mM BI-D1870 prior to stimulation of U46619.
doi:10.1371/journal.pone.0058703.g002
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Figure 3. RSK and PDK1 contribute to Ca2+-induced force, MYPT1 and RLC20 phosphorylation in a-toxin permeabilized rabbit
pulmonary artery SM. RSK inhibitor, BI-D1870 is without effect on the actomyosin ATPase. (A) RSK inhibitor, BI-D1870 (100nM), right shifted the
pCa2+-force relationship and decreased the maximal force (milli-Newtons, mN) at each intracellular Ca2+ concentration (pCa) compared to the Control
diluent, DMSO. (B) BI-D1870 (100 nM) decreased phosphorylation of MYPT1 Thr853 (n = 3) and RLC20 phosphorylation at Ser19 (n = 4) at maximal
Ca2+-induced (pCa 4.5) force. (C) BI-D1870 (100 nM) was without effect on the ATP-induced rate of force development in Triton permeabilized mouse
ileum SM with pre-thiophosphorylated light chains and depleted of ATP. T1/2= 4.861.2 sec vs 5.061.3 sec in the Control (DMSO) vs BI-D1870
respectively, p = ns, n = 3. Thus, the inhibitor effects of BI-D18670 are not due to inhibition of the actomyosin ATPase. (D) The PDK1 kinase inhibitor
GSK 2334470 (30 mM) also suppressed the pCa2+-force relationship and reduced the absolute force (mN).
doi:10.1371/journal.pone.0058703.g003
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42610.5%, n= 3, p,0.01; following stimulation with U46619,
but no change was detected with high [K+] stimulation (Figure 7A).
The phosphorylation level of Ser668 was also increased by ,45%
in a-toxin permeabilized SM strips stimulated by Ca2+ (pCa 7.0)
and U46619 (Figure 7B). The functional significance of this
phosphorylation remains to be determined.
Discussion
Dysregulation of SM contractility is an underlying factor in
several pathophysiological phenomena, such as hypertension,
asthma, bowel disease, cerebral vasospasm and others [33]. Given
the prevalence of hypertension alone, and the fact that many
patients do not respond to available medications, there is an
ongoing search for alternative therapies targeting specific signaling
pathways. Detailed characterization of all physiological regulatory
pathways in SM tissues is a prerequisite for identification of
suitable targets for drug discovery. To date, only the ROCK
kinase, involved in Ca2+-sensitization has been considered a valid
drug target, but the ubiquitous distribution of ROCK and its
many physiological functions raise concerns about side effects.
Nevertheless, fasudil a potent ROCK inhibitor (currently in
clinical trials in the US), is used in Japan to treat cerebral
vasospasm [34]. A possible involvement of other kinases in the
Ca2+-induced contraction and sensitized force opens alternative
avenues for drug discoveries.
It has long been recognized that kinases other than MLCK may
operate in SM, such as the Ca2+-independent kinases zipper-
interacting protein kinase (ZIPK) [32,35] and the integrin-linked
kinase (ILK) [36,37]. An interesting variation of this scheme
involves Ca2+-independent kinases, such as proline-directed
kinases [38,39,40], acting indirectly on RLC20, by phosphorylating
and up-regulating MLCK.
We were intrigued by a report that the p90 ribosomal S6
protein kinase (RSK2) was also able to phosphorylate RLC20 in
vitro. The involvement of RSK kinases in SM contraction has
never been investigated before, although their presence in SM is
relatively well documented [41]. Similarly, the presence in SM of
ERK1/2 kinases, and the constitutively active PDK1 kinase has
Figure 4. RSK functions as a Ca2+ independent kinase to increase force and RLC20 phosphorylation. RSK inhibition increases the time to
the onset of force and the rate of force development (t1/2) induced by the MLCP (PP1C) inhibitor microcystin-LR (10 mM) in the absence of Ca2+(pCa
9.0) The relative phosphorylation of RLC20, measured at 25 min following the addition of microcystin, was decreased in the presence of BI-D1870
(1 mM).
doi:10.1371/journal.pone.0058703.g004
Figure 5. The RSK inhibitor BI-D1870 does not function
through inhibition of ZIP kinase. The elution of full length GFP-
ZIPK off of c phosphate linked ATP resin in the presence of 100 mM
ATP, 50mM BI-D1870 or blank buffer (2% DMSO) is shown. We used
100 mM ATP because of the dense resin concentration (10 mM).
100 mM ATP gives a maximal signal. The small signal given by BI-D1870
above background (2% DMSO) is not considered relevant.
doi:10.1371/journal.pone.0058703.g005
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also been established [19,33,42,43]. However, to our knowledge
no direct study has implicated RSK in physiological SM
contractility. To inhibit the RSK activity we used two recently
described selective inhibitors, the naturally occurring, rare flavonol
glycoside kaempferol-3-O-(3’’,4’’-di-O-acetyl-a-L-rhamnopyrano-
side) (SL0101) [20] and the unrelated synthetic compound BI-
D1870 derived from the pyrido[2,3-d]pyridimidine group of Src
inhibitors [21]. A recent study of a large panel of protein kinases
showed that neither SL0101 nor BI-D1870 has any inhibitory
effect on the two principal kinases in SM contractility pathways,
i.e. MLCK or ROCK, [29]. Thus, the effects described in our
study are highly unlikely to be due to off-target phenomena. The
use of selective kinase inhibitors circumvented the need for a time-
intensive gene silencing procedure, and we were able to use fresh
pulmonary artery strips for technically easy, direct force measure-
ments. We next plan to generate RSK2/RSK3 null SM cells to
further explore the contribution of RSK to vascular contractility
and basal tone.
Our data show, for the first time, that RSK kinases are indeed
involved in SM contractility. We found, that in the a-toxin
permeabilized rabbit pulmonary artery the RSK inhibitor BI-
D1780 significantly decreased the contractile force response to
[Ca2+], and shifted the onset of contraction to pCa 7.1 from pCa
of 8.0. Furthermore, BI-D1870 also inhibited contractions elicited
Figure 6. RSK and MEK/ERK signaling pathways contribute to TXA2-induced Ca
2+ sensitized force and MYPT1 and RLC20
phosphorylation in a-toxin permeabilized rabbit pulmonary artery SM. (A) U46619 (300 nM) induced Ca2+ sensitized force is suppressed in
the presence of RSK inhibitor, BI-D1870 (100 nM). Subsequent addition of GTPcS, as a measure of the remaining component of Ca2+ sensitized force,
reached the same magnitude of force but was proportionately greater in the presence of the RSK inhibitor BI-D1870 than in its absence. (B) Summary
of panel A along with an effect of PDK1 kinase inhibitor GSK2334470 (30 mM) on U46619-induced force. (C) RSK inhibitor, BI-D1870 (1 mM)
significantly inhibited the U46619 (300 nM) increased phosphorylation of MYPT1 Thr853 (n = 3), RLC20 phosphorylation at Ser19 (n = 5) and MYPT1
Thr696 phosphorylation (n = 5). (D) Unphosphorylated (0P), singly (1P) and doubly phosphorylated (2P) RLC20 from SM samples stimulated with
U46619 with and without BI-D1870 as in panel C were separated on urea gels. A positive control for doubly phosphorylated RLC20 was a b-escin
treated SM stimulated with microcystin. (E) U46619 stimulation increased the phosphorylation of proteins that regulate RSK activation; RSK2 Ser227
(n = 8), ERK1/2 (n = 7) and PDK1 Ser241(n = 15).
doi:10.1371/journal.pone.0058703.g006
Figure 7. MYPT1 phosphorylation at Ser668 is increased upon stimulation with the TXA2 analogue, U46619, in permeabilized and
intact pulmonary artery SM but not by high [K+] stimulation in intact SM. (A) U46619 (300 nM) (n = 3) but not high [K+] stimulation
increases phosphorylation of MYPT1 Ser668 in intact pulmonary artery smooth muscle. (B) Increasing Ca2+ to pCa7.0 with and without U46619
(300 nM) induced Ca2+ sensitized force in a-toxin permeabilized SM significantly increased phosphorylation of MYPT1 at Ser668 compared to control
muscles in G1 solution pCa,8.0 (5969.6%, n = 10, p,0.01).
doi:10.1371/journal.pone.0058703.g007
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by high [K+] and U46619 in intact SM demonstrating that the
observed effects in permeabilized SM are not merely due to loss of
cytoplasmic components. Our findings were not expected, because
RSK kinases have been associated primarily with signaling
downstream of growth factors and receptor tyrosine kinases and
are thought to play key roles in cell cycle progression, cell growth,
survival and proliferation [30]. To dissect the specific pathway
through which RSK potentiates Ca2+-induced contraction, we
analyzed the phosphorylation levels of both RLC20 and MYPT1
in the presence of inhibitor. Both proteins were phosphorylated on
the canonical regulatory sites, Ser19 and Thr853 respectively, at a
significantly higher level in the absence of inhibitors, strongly
suggesting that RSK simultaneously up-regulates myosin and
down-regulates MLCP, resulting in a significant contribution to
contractility. We also demonstrated that the mechanism of action
of the RSK inhibitor is not through inhibition of the SM
actomyosin ATPase.
It is not clear at this point in what way increased Ca2+
concentration may activate RSK. Again, this observation is not per
se novel, as it has been already reported that in growth arrested
cultured vascular SM cells angiotensin II increased RSK activity
which was inhibited (directly or indirectly) by chelation of
intracellular Ca2+ [41]. Several options linking Ca2+ to RSK
activation have been discussed in literature [44,45]. One distinct
possibility is that another Ca2+-dependent kinase functions up-
stream of RSK. For example, calmodulin-dependent kinase I
(CaMKI) has been shown under some conditions to mediate the
activation of the ERK1/2 kinases, which prime RSK for
phosphorylation and activation by PDK1, by elevated intracellular
[Ca2+] [46]. The precise pathway by which RSK may be linked to
[Ca2+]-induced signaling in vascular SM is under investigation in
our group.
A new, exciting discovery reported in this paper is that BI-
D1870 has a significant impact on the phosphorylation of
MYPT1, suggesting that inhibition of MLCP may constitute an
important mechanism by which RSK potentiates the contractile
force. Moreover, we determined that in response to stimulation by
the thromboxane A2 analogue U46619 at constant pCa, RSK
phosphorylates MYPT1 at Thr696 and Thr853, the two known
inhibitory sites. Both these sites are targets for the RhoA-
dependent ROCK kinase and their phosphorylation accounts for
the Ca2+-sensitization effect [47], but both also conform to the
established RSK-consensus phosphorylation sequence motif
RRX(S/T). This Ca2+-independent mechanism is also consistent
with the decreased sensitivity to Ca2+ in inhibitor treated samples
(Figure 3), as higher Ca2+ concentrations are required to trigger
contraction in the presence of up-regulated (or rather uninhibited)
activity of MLCP. Thus, RSK may be recruited in agonist-
stimulated Ca2+-sensitization, through a pathway canonically
identified with ROCK, as well as acting as a Ca2+-independent
MLCK.
One of the interesting outcomes of our study is the identification
of the third potential phosphorylation site in MYPT1, i.e. Ser668.
This is one of several sites in MYPT1 reported by Cell Signaling
Technology using LC-MS/MS platform to be phosphorylated in a
number of human cancers [48]. Insulin has also been shown to
Figure 8. Ribosomal S6 kinase (RSK) signaling scheme for regulation of Ca2+-independendent contraction of smooth muscle.
Agonists through GPCRs leads to activation of sequential ERK1/2 phosphorylations of RSK, subsequent RSK autophosphorylation by its C-terminal
kinase domain (CTKD), the recruitment of phosphoinositide-dependent kinase 1 (PDK1) to this newly phosphorylated site, and finally PDK1-
dependent phosphorylation at Ser227, with concomitant activation of the NTKD. Active RSK increases RLC20 phosphorylation, either directly or
indirectly, as well as inhibitory phosphorylation of MYPT1 at Thr696/853 augmenting Rho/ROCK phosphorylation of these sites. Potential RSK
phosphorylation of Ser668 on MYPT1 is also indicated.
doi:10.1371/journal.pone.0058703.g008
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result in MYPT1 phosphorylation at Ser668 [49], although
neither the function of this phosphorylation nor the responsible
kinase have been identified. Protein kinase G (PKG1a) known to
selectively phosphorylate MYPT1 isoforms that include a C-
terminal leucine zipper has also been shown to phosphorylate
MYPT1 on Ser668 in vitro [50]. This is not surprising, as PKG,
PKA and RSK kinases all belong to the AGC kinase group and
have similar phosphorylation motifs. However, cyclic nucleotides
lead to Ca2+ desensitization and relaxation of SM [6], whereas
activation of RSK is expected to result from agonist activation that
increase ERK activation leading to contraction of SM [17].
Perhaps the functional outcome of Ser688 phosphorylation may
depend on whether other sites on MYPT1 are phosphorylated,
and if the combined structural effects lead to activation or
inhibition of MLCP activity on myosin. Details of this mechanism
remain to be determined.
The activation of RSK kinases involves several sequential
phosphorylation steps, initiated by the docking of extracellular
signal-regulated kinases (ERK1/2) at the C-terminus with
subsequent phosphorylation and activation of CTKD. Our
findings that U-46619-induced Ca2+ sensitized force, MLC20
and MYPT1 phosphorylation correlates with an increase in
phosphorylated ERK1/2, RSK2 S227 and PDK1 S241 are all
consistent with agonist-induced RSK activation. However, the
original in vitro observations that p42MAPK suppressed the ability
of RSK2 (in the absence of CTKD) to phosphorylate RLC20 but
not a C-terminal peptide of human 40S ribosomal protein S6 [11]
is inconsistent with our findings and hypothesis. This difference
may be due to the use of in vitro vs in vivo protocols and if so, reflects
the importance of intracellular compartmentalization and con-
centrations of signaling molecules. One possible further explana-
tion of the discrepancy in the findings is that in vivo activated RSK
may preferentially phosphorylate MYPT1 rather than directly
phosphorylate RLC20.
While the activation of the ERK1/2 pathway by the
thromboxane A2 receptor in SM has been reported before [51],
the physiological consequences for SM contractility are described
here to our knowledge for the first time. Inhibition of ERK1/2
and p38MAPK have been previously shown to suppress the Ca2+-
independent protein kinase activity observed with microcystin-
induced force in rat ileal SM at 1 mM microcystin [52]. At 10 mM
microcystin, where PP1C was maximally inhibited, ERK1/2 and
p38MAPK inhibitors had no effect. In this same study, inhibition
of ROCK with Y-27632 or ZIPK with SM1 peptide had no effect,
prompting the authors to suggest that ERK1/2 and p38MAPK
are contributing to ILK-mediated inhibition of MLCP activity.
Based on the present findings, we suggest that RSKs are the
physiological ERK1/2 substrates, perhaps in addition to ILK. An
interesting difference between the experiments utilizing RSK
inhibitors (our study) and those using ERK1/2, p38MAPK and
PKC inhibitors (the earlier study of ileal SM [52]) is that in the
pulmonary artery the RSK inhibitors are very effective in
inhibiting the rate and lag phase of force development at 10 mM
microcystin, a concentration at which the other inhibitors had no
effect on the ileum. Based on our evidence for phosphorylation
and activation of ERK1/2 and RSK, we conclude that in the
pulmonary artery, unlike in the ileum, the force developed at
10 mM microcystin at pCa 9.0 reflects the ERK/RSK-mediated
phosphorylation of RLC20. The residual microcystin-induced
force in the presence of the RSK inhibitor reflects the activity of
other Ca2+ independent kinases such as ZIPK consistent with our
finding that ZIPK is not eluted from a c-phosphate linked ATP
resin by BI-D1870. Constitutively active ILK is unavailable for
testing.
Altogether, our findings demonstrate that the canonical
upstream RSK activation signaling pathways established in other
cell types are present and activated in SM, supporting a novel
function for p90 ribosomal S6 kinases in the regulation of SM
contractility (Figure 8). It remains to be shown whether the RSK
signaling pathway also contributes to myosin-based motility of
non-muscle cells and whether it contributes to deregulated
contractility in diseases of SM.
Supporting Information
Figure S1 (A) Western Blot analysis shows absence of cross-
reactivity of anti-RSK1 and anti-RSK3 antibodies with RSK2. (B)
Expression profile of RSK1 and RSK2 in rabbit and mouse
smooth muscle tissues. Positive control: over-expressed truncated
RSK2. (*: the quantity of uterus protein sample loaded for RSK2
is half of all other mouse samples. (C) Alignment of C-terminal
part of human (h), mouse(m) and rabbit(rab) RSK isoforms used
for the commercial antibody production. Note the perfect
homology between species for given isoforms RSK1 and RSK2.
Therefore, the presence of RSK1 protein in rabbit but not mouse
smooth muscle tissues is not due to differences in antigen sequence.
(TIF)
Figure S2 Dose-response curves for RSK inhibitors (BI-D1870
and SL0101-1), PDK inhibitor (GSK2334470) and corresponding
concentrations of the diluent, DMSO carried out in a-toxin
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